10x Genomics
320 hedge funds and large institutions have $1.44B invested in 10x Genomics in 2025 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 98 increasing their positions, 91 reducing their positions, and 41 closing their positions.
113% more call options, than puts
Call options by funds: $5.96M | Put options by funds: $2.8M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
61% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 41
7% more funds holding
Funds holding: 299 → 320 (+21)
8% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 91
4% more capital inflows, than outflows
Capital inflows: $275M | Capital outflows: $264M
2.88% less ownership
Funds ownership: 110.37% → 107.49% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$33.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.2M |
| 3 |
Goldman Sachs
New York
|
+$27M |
| 4 |
Quantinno Capital Management
New York
|
+$16.4M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
-$26.1M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$22.1M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$18.4M |
| 4 |
Blue Water Life Science Advisors
Larkspur,
California
|
-$12.7M |
| 5 |
Jump Financial
Chicago,
Illinois
|
-$12.5M |
TXG Hedge Fund Activity: Q3 2025 in Review
320 of the 7,663 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2025, worth a combined $1.44B — up 1.2% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new TXG positions and 41 closed out — a net gain of 25 holders — while 98 added to existing stakes and 91 trimmed.
The largest buyer was Millennium Management, adding an estimated $33.3M. The largest seller was ARK Investment Management, cutting an estimated $26.1M.
- 320 institutional investors held 10x Genomics (TXG) as of Q3 2025, up from 299 in Q2 2025.
- Funds reported $1.44B of 10x Genomics stock for Q3 2025, up 1.2% quarter-over-quarter.
- 66 funds opened new 10x Genomics positions in Q3 2025 and 41 closed out, a net change of +25 holders.
- The largest 10x Genomics buyer in Q3 2025 was Millennium Management, an estimated $33.3M added.
- The largest 10x Genomics seller in Q3 2025 was ARK Investment Management, an estimated $26.1M sold.
Based on aggregated 13F filings for Q3 2025.